HC Wainwright reaffirmed their neutral rating on shares of Adicet Bio (NASDAQ:ACET - Free Report) in a research note published on Thursday,Benzinga reports.
A number of other brokerages have also recently issued reports on ACET. StockNews.com cut Adicet Bio from a "hold" rating to a "sell" rating in a report on Tuesday, November 19th. Wedbush reiterated an "outperform" rating and issued a $5.00 price objective on shares of Adicet Bio in a report on Thursday, November 7th. Finally, JMP Securities reiterated a "market perform" rating on shares of Adicet Bio in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $7.50.
View Our Latest Stock Report on ACET
Adicet Bio Stock Down 5.7 %
Shares of NASDAQ ACET traded down $0.05 during midday trading on Thursday, reaching $0.85. 361,354 shares of the company were exchanged, compared to its average volume of 1,038,991. The stock's 50-day moving average price is $0.94 and its 200-day moving average price is $1.17. The stock has a market cap of $69.84 million, a P/E ratio of -0.50 and a beta of 1.86. Adicet Bio has a one year low of $0.81 and a one year high of $2.54.
Hedge Funds Weigh In On Adicet Bio
A number of hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in Adicet Bio in the fourth quarter valued at approximately $29,000. GSA Capital Partners LLP boosted its stake in shares of Adicet Bio by 161.3% in the 3rd quarter. GSA Capital Partners LLP now owns 39,208 shares of the company's stock valued at $56,000 after purchasing an additional 24,203 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Adicet Bio by 10,321.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 80,353 shares of the company's stock valued at $116,000 after purchasing an additional 79,582 shares during the last quarter. Northern Trust Corp increased its position in shares of Adicet Bio by 25.1% during the fourth quarter. Northern Trust Corp now owns 140,369 shares of the company's stock worth $135,000 after buying an additional 28,153 shares during the period. Finally, Squarepoint Ops LLC bought a new position in Adicet Bio during the fourth quarter worth $177,000. 83.89% of the stock is currently owned by institutional investors.
About Adicet Bio
(
Get Free Report)
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Further Reading
Before you consider Adicet Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adicet Bio wasn't on the list.
While Adicet Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
